Targets › CRBN
18 programs from 10 companies in 252 trials: 139 Phase 2, 75 Phase 1, 37 Phase 3, 1 Phase 4; Oncology, Hematology, Other; next expected readout Nov 2026.
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2, ILF2, GLUL, IKZF1 and CSNK1A1. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. (UniProt, Q96SW2)
Open in Phaseline: the race on CRBN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | CC-92480 (BMS-986348, mezigdomide) Cereblon E3 ligase modulator (cereblon-binding protein that promotes IKZF1 and IKZF3 degra | CRBN | Phase 3 | Relapsed or Refractory Multiple Myeloma; Multiple Myeloma | Nov 2026 |
| National Cancer Institute (NCI) | Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | DS Stage I Multiple Myeloma; Multiple Myeloma | Feb 2027 |
| Incyte | Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma; Newly Diagnosed … | Apr 2027 |
| Bristol-Myers Squibb | Golcadomide (CC-99282, BMS-986369) Cereblon E3 ligase modulator; dual IKZF1/IKZF3 degrader | CRBN, IKZF1, IKZF3 | Phase 3 | Large B-cell Lymphoma; Follicular Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin … | Apr 2027 |
| Beijing InnoCare Pharma Tech | Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | DLBCL | Apr 2027 |
| University of Arkansas | Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Multiple Myeloma; Myeloma | Aug 2027 |
| Bristol-Myers Squibb | Iberdomide CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Multiple Myeloma; Lymphoma, B-Cell; Newly Diagnosed Multiple Myeloma; Smoldering Plasma Cell Myeloma … | Nov 2027 |
| Shandong New Time Pharmaceutical | Pomalidomide (F182112) CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM); Relapsed or Refractory Multiple Myeloma; Systemic Lupus Erythematosus (SLE); Multiple Myeloma … | Dec 2027 |
| Bristol-Myers Squibb | Mezigdomide Cereblon E3 ubiquitin ligase modulator (CRBN modulator) | CRBN | Phase 3 | Relapsed or Refractory Multiple Myeloma | Jul 2029 |
| CellCentric | Pomalidomide (CCS1477) CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Multiple Myeloma Refractory | Nov 2029 |
| Roche | Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Relapsed or Refractory Follicular Lymphoma; Follicular Lymphoma | Dec 2029 |
| Fondazione Italiana Linfomi - ETS | CC-99282 (Golcadomide) Cereblon-binding IMiD (immunomodulatory imide drug) with anti-tumor and immunostimulatory | CRBN | Phase 2 | Diffuse Large B Cell Non-Hodgkin Lymphoma | Apr 2030 |
| National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 2 | Fetal Hemoglobin | – |
| Bristol-Myers Squibb | CC-122 (also: Avadomide, BMS-986381) Cereblon E3 ligase modulator | CRBN | Phase 1 | Non-Hodgkin Lymphoma | Nov 2026 |
| Bristol-Myers Squibb | Golcadomide (BMS-986369, CC-99282) Cereblon (CRBN) E3 ligase modulator | CRBN | Phase 1 | Kidney Failure, Chronic; Relapsed/Refractory Non-Hodgkin Lymphoma; Relapsed or Refractory T-cell Lymphomas | Dec 2026 |
| Roche | Iberdomide (CC-220) CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 1 | Multiple Myeloma; Non-Hodgkin Lymphoma | Jul 2028 |
| Bristol-Myers Squibb | Iberdomide (BMS-986382) CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 1 | Multiple Myeloma | Aug 2028 |
| Bristol-Myers Squibb | Mezigdomide (BMS-986348, CC-92480) Cereblon E3 ubiquitin ligase modulator | CRBN | Phase 1 | Multiple Myeloma; Extramedullary Disease in Multiple Myeloma; KMT2A-rearranged; Relapsed Refractory Multiple Myeloma (RRMM) … | Aug 2028 |
Multiple Myeloma (59) Follicular Lymphoma (7) Plasma Cell Myeloma (7) Mantle Cell Lymphoma (6) DLBCL (5) Relapsed or Refractory Multiple Myeloma (5) Recurrent Multiple Myeloma (4) Diffuse Large B-cell Lymphoma (4) DS Stage I Multiple Myeloma (4) Multiple Myeloma in Relapse (4) Myeloma (3) Non-Hodgkin Lymphoma (3)
mixed (11), small molecule (6), antibody (1)
Bristol-Myers Squibb (8) Roche (2) University of Arkansas (1) National Institute of Blood and Marrow Transplant (NIBMT), Pakistan (1) Incyte (1) National Cancer Institute (NCI) (1) Shandong New Time Pharmaceutical (1) Beijing InnoCare Pharma Tech (1) Fondazione Italiana Linfomi - ETS (1) CellCentric (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.